Esperion Therapeutics (NASDAQ:ESPR), a tiny, Plymouth, Mich based developer of cholesterol drugs, recently started Phase 2b trials of its compound ETC-1002. The trial enrolls people who cannot tolerate statins and/or have high LDL-C (bad cholesterol) levels that they cannot control.
ETC-1002 is a once-daily, oral, small molecule drug that lowers the level of LDL-C and avoids the side effects caused by statins.
The goal of the trial is to compare the LDL-C lowering efficacy of ETC-1002 taken with ezetimibe and to demonstrate that it is as tolerable as ezetimibe. Ezetimibe is a drug commonly used for statin intolerance. A patient is considered statin intolerant if he or she cannot tolerate two or more statins administered at or below...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|